secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-01-16T23:59:59+00:00
Accession:  0001104659-25-004132
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin reports positive QRX003 data in Netherton Syndrome: IGA improves from severe to mild after 6 weeks
--------------------------------------------------------------------------------

- IGA score improved from 'severe' at baseline to 'mild' after six weeks of twice-daily QRX003 dosing.
- After 12 days of dosing, IGA was 'mild-moderate'; full 6-week data confirms continued improvement.
- Subject transitioned from 20% BSA treatment to whole-body application based on positive results.
- No adverse events or safety concerns reported for this subject, consistent with prior studies.
- Data from ongoing 12-week Investigator Pediatric Study supports QRX003's potential in Netherton Syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925004132/0001104659-25-004132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925004132/tm253523d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-004132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer